Far out just read the question that is one hardcore no on Rem-L from the author. Seems to be focusing on the missed endpoints alot. Does the drawn target analogy have meaning in this context as we have found Rem-L to be effacious in the covid ARDS extension. Some rebuttal points that immediately come to mind are consistency and dosage has been improved since the original trials at Osiris? Or am I getting confused with another label in the MSB range.
Cell Therapy News/Articles, page-5209
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.065(4.66%) |
Mkt cap ! $1.684B | |||
| Open | High | Low | Value | Volume |
| $1.41 | $1.50 | $1.40 | $5.699M | 3.943M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 122380 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 11015 | 2 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |